MX2021008326A - Anticuerpos contra tim-3 y combinaciones con otros inhibidores de puntos de regulacion para el tratamiento del cancer. - Google Patents
Anticuerpos contra tim-3 y combinaciones con otros inhibidores de puntos de regulacion para el tratamiento del cancer.Info
- Publication number
- MX2021008326A MX2021008326A MX2021008326A MX2021008326A MX2021008326A MX 2021008326 A MX2021008326 A MX 2021008326A MX 2021008326 A MX2021008326 A MX 2021008326A MX 2021008326 A MX2021008326 A MX 2021008326A MX 2021008326 A MX2021008326 A MX 2021008326A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- tim
- treatment
- cancer
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a regímenes de dosificación para anticuerpos que se unen a la proteína 3 que contiene dominio de mucina e inmunoglobulina de células T (TIM-3) humana, y puede ser útil para tratar tumores en combinación con anticuerpos anti-PD-L1 humano, anticuerpos anti-PD-1 humano, quimioterapia y radiación ionizante, así como el uso de dichos anticuerpos para el tratamiento de tumores sólidos que son deficientes en la reparación de errores de apareamiento o exhiben un alto grado de inestabilidad de microsatélites.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962791077P | 2019-01-11 | 2019-01-11 | |
PCT/US2020/012118 WO2020146196A1 (en) | 2019-01-11 | 2020-01-03 | Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021008326A true MX2021008326A (es) | 2021-08-05 |
Family
ID=69423408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021008326A MX2021008326A (es) | 2019-01-11 | 2020-01-03 | Anticuerpos contra tim-3 y combinaciones con otros inhibidores de puntos de regulacion para el tratamiento del cancer. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220089740A1 (es) |
EP (1) | EP3908610A1 (es) |
JP (1) | JP2022517087A (es) |
KR (1) | KR20210102327A (es) |
CN (1) | CN113272331A (es) |
AU (1) | AU2020207132A1 (es) |
BR (1) | BR112021010703A2 (es) |
CA (1) | CA3126133A1 (es) |
EA (1) | EA202191526A1 (es) |
IL (1) | IL284320A (es) |
MX (1) | MX2021008326A (es) |
WO (1) | WO2020146196A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113866416B (zh) * | 2021-10-20 | 2022-06-24 | 山东大学 | 可溶形式Tim3在免疫检查点阻断治疗抵抗的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
WO2017205213A1 (en) * | 2016-05-23 | 2017-11-30 | Eli Lilly And Company | Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer |
JOP20190013A1 (ar) * | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
AU2017354070A1 (en) | 2016-11-01 | 2019-05-16 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (PD-1) |
CA3043761C (en) * | 2016-12-08 | 2022-08-09 | Eli Lilly And Company | Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies |
JOP20190133A1 (ar) * | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
AU2018205401A1 (en) * | 2017-01-09 | 2019-07-25 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
WO2019006007A1 (en) * | 2017-06-27 | 2019-01-03 | Novartis Ag | POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF |
-
2020
- 2020-01-03 WO PCT/US2020/012118 patent/WO2020146196A1/en unknown
- 2020-01-03 AU AU2020207132A patent/AU2020207132A1/en not_active Abandoned
- 2020-01-03 JP JP2021540232A patent/JP2022517087A/ja active Pending
- 2020-01-03 BR BR112021010703-7A patent/BR112021010703A2/pt not_active IP Right Cessation
- 2020-01-03 US US17/420,189 patent/US20220089740A1/en active Pending
- 2020-01-03 MX MX2021008326A patent/MX2021008326A/es unknown
- 2020-01-03 EA EA202191526A patent/EA202191526A1/ru unknown
- 2020-01-03 CA CA3126133A patent/CA3126133A1/en not_active Abandoned
- 2020-01-03 CN CN202080008897.6A patent/CN113272331A/zh active Pending
- 2020-01-03 KR KR1020217021225A patent/KR20210102327A/ko not_active Application Discontinuation
- 2020-01-03 EP EP20703324.2A patent/EP3908610A1/en not_active Withdrawn
-
2021
- 2021-06-23 IL IL284320A patent/IL284320A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220089740A1 (en) | 2022-03-24 |
WO2020146196A1 (en) | 2020-07-16 |
CA3126133A1 (en) | 2020-07-16 |
CN113272331A (zh) | 2021-08-17 |
IL284320A (en) | 2021-08-31 |
KR20210102327A (ko) | 2021-08-19 |
AU2020207132A1 (en) | 2021-06-24 |
EA202191526A1 (ru) | 2021-10-05 |
EP3908610A1 (en) | 2021-11-17 |
JP2022517087A (ja) | 2022-03-04 |
BR112021010703A2 (pt) | 2021-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
PH12020500075A1 (en) | Checkpoint inhibitor bispecific antibodies | |
PH12019500369A1 (en) | Anti-tim-3 antibodies | |
MX2019002474A (es) | Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres. | |
MY195110A (en) | Antibodies to PD-1 and uses Thereof | |
MY199019A (en) | Pd-1 antibodies | |
MX2020010604A (es) | Terapia de combinacion anticancer con anticuerpo antagonista del grupo de diferenciacion 73 (cd73) y anticuerpo antagonista del eje proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1). | |
JOP20210314A1 (ar) | Tigit وجزيئات ربط pd-1/tigit | |
EA202190181A1 (ru) | Композиции и способы для направленной иммунотерапии flt3, pd-1 и/или pd-l1 | |
WO2019036031A3 (en) | Immunotherapeutic tumor treatment method | |
WO2018102589A3 (en) | Anti-hrs antibodies and combination therapies for treating cancers | |
JOP20200016B1 (ar) | أجسام مضادة لـ cd137 | |
MX2022004766A (es) | Terapias combinadas con venetoclax e inhibidores de tim-3. | |
MX2021005236A (es) | Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer. | |
NZ756581A (en) | Anti-pd-l1-anti-tim-3 bispecific antibodies | |
MX2020009864A (es) | Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1. | |
MX2018009621A (es) | Combinaciones de dihidrocloruro de histamina y uso de estas. | |
MX2021008326A (es) | Anticuerpos contra tim-3 y combinaciones con otros inhibidores de puntos de regulacion para el tratamiento del cancer. | |
MX2020009863A (es) | Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-l1. | |
MX2021011034A (es) | Metodos y composiciones para el tratamiento del cancer. | |
MX2023006777A (es) | Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2). | |
MX2023007780A (es) | Terapia de combinacion usando un anticuerpo anti-fucosil-gm1. | |
EA202092733A1 (ru) | Ингибиторы pd-1/pd-l1 | |
EA201992045A1 (ru) | Ингибиторы pd-1/pd-l1 |